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Infrared spectroscopy is a reliable, rapid and cost effective characterisation technique, 
delivering a molecular finger print of the sample. It is expected that its sensitivity would enable 
detection of small chemical variations in biological samples associated with disease. ATR-IR 
is particularly suitable for liquid sample analysis and, although air drying is commonly 
performed before data collection, just a drop of human serum is enough for screening and early 
diagnosis. However, the dynamic range of constituent biochemical concentrations in the serum 
composition remains a limiting factor to the reliability of the technique. Using glucose as a 
model spike in human serum, it has been demonstrated in the present study that fractionating 
the serum prior to spectroscopic analysis can considerably improve the precision and accuracy 
of quantitative models based on the Partial Least Squares Regression algorithm. By depleting 
the abundant high molecular weight proteins, which otherwise dominate the spectral signatures 
collected, the ability to monitor changes in the concentrations of the low molecular weight 
constituents is enhanced. The Root Mean Square Error for the Validation set (RMSEV) has 
been improved by a factor of 5 following human serum processing with an average relative 
error in the predictive values below 1% is achieved. Moreover, the approach is easily 
transferable to different bodily fluids, which would support the development of more efficient 
and suitable clinical protocols for exploration of vibrational spectroscopy based ex-vivo 





1.  Introduction 
 
Bodily fluids have become a much investigated source of samples for the development of rapid 
and cost effective diagnostic methods1-4. Reducing the invasiveness of the current approaches 
to get molecular information linked to pathological events occurring in different organs 
affected by various diseases is naturally one of main challenges to improve the patients¶ 
comfort. Therefore, performing analysis directly on a few microliters of serum, plasma, saliva 
or urine has attracted great interest in the medical field, especially due to the facile specimen 
collection. Blood analysis still holds much promise for accurate ex vivo diagnostics and, 
compared to deep tissue biopsies, often requiring extreme interventions, the reduced 
invasiveness of the syringe remains a quite acceptable alternative.  
Human serum (or plasma) is a vast reservoir for biochemical products collected and 
accumulated while perfusing the different organs of the body5, ultimately reflecting the 
physiological status of a patient. It is expected that modifications in its overall composition 
could indicate the presence of disease and consequently deliver a diagnostic based on specific 
molecular signatures6. It is well accepted that proteins secreted and shed from cells and tissues, 
such as prostate-specific antigen (PSA) and CA125, can be identified routinely and act as 
biomarkers of disease7. In addition, proteolysis within the tissue or deregulated post-
translational events participate in fragmentation of proteins produced in tumours that diffuse 
into the circulation6. This is further supported by recent associations of pathological conditions 
with small protein and peptide profiles in serum, notably for diabetes8, cardiovascular or 
infectious diseases9. The number of studies related to serum proteomics, peptidomics or 
metabololics has literally exploded in the literature, complex analytical techniques such as 
chromatography and/or mass spectroscopy being the reference tools10, 11. Quite naturally, 
vibrational spectroscopy, which has been widely employed in biomedical analysis, from tissue 
sections12, 13 to single cells14, 15 with a well demonstrated potential for diagnosis16, 17, has the 
capability to become the next generation gold standard tool for serum based patient screening18-
20. The advent of imaging technologies coupled to the rapid data collection offered by FTIR 
systems has contributed considerably to the attraction of infrared absorption spectroscopy for 
biomedical applications21-23. However, other methods such as ATR-FTIR are highly suitable 
for analysis of liquid samples, such as body fluids, allowing delivery of chemical fingerprints 
from micro-deposition of the samples directly on the Attenuated Total Reflection (ATR) 
crystal24, 25. The IR spectrum contains rich and specific information about the molecular 
composition of the human serum which, coupled to advanced multivariate analysis tools, could 
deliver accurate diagnostics. Recent systematic studies have demonstrated the potential of IR 
serum based diagnosis with different data mining approaches such as Principal Components 
Analysis (PCA), PCA coupled to Linear Discriminant Analysis (PCA-LDA), Random Forest 
or Support Vector Machine (SVM)26-30. However, the development of spectroscopic 
technologies with medical perspectives needs to align with clinical requirements to enable 
clinical translation of these promising technologies31. Although infrared and Raman 
spectroscopy have great potential for serum based detection of disease biomarkers32, 33, in many 
cases, detection of the presence of a biomarker is not sufficient, but rather quantification within 
a physiologically relevant range is required, a common example being glucose levels in 
blood.34.   
Partial Least Squares Regression analysis (PLSR) remains one of most used analysis methods 
for quantitative models35 either in different body fluids such as urine36, saliva37, 38, serum39 or 
to evaluate physiological responses to drugs in cells40. However, the serum composition is 
highly complex, with up to 10,000 different proteins in an overall concentration ranging from 
60 to 80 mg/mL. Moreover, other circulating molecular species such as sugars, lipids, peptides, 
metabolites are present, adding to the complexity of the mixture and consequently making 
quantitative analysis of variations in individual constituents a challenging task. Human serum 
is also characterized by the dynamic range of concentrations observed between the abundant, 
high molecular weight (HMW) and the sparse, low molecular weight (LMW) molecules. For 
example, human serum albumin (HSA) (57±71%) and globulins (8±26%) are two abundant 
HMW proteins completely dominating the composition of the serum quantitatively, potentially 
impacting the detection and monitoring small variations in the features related to the presence 
of the informative low molecular weight proteins/peptides/metabolites41. The analytical 
capabilities of traditional proteomic methods are limited, given this large dynamic range of 
concentrations in the serum. Therefore, depletion of the highly abundant proteins is now 
recognized as the first step, yet to be optimized, in the analysis of the serum composition42. 
ATR-FTIR suffers from similar limitations to those encountered with chromatography and/or 
mass spectroscopy based approaches, which can be overcome by means of sample fractionation 
prior to data recording24. Including a separation step prior to IR analysis in order to enhance 
the specificity and sensitivity have been proposed through coupling with chromatography 
technologies such as LC-IR and GC-IR43. Those hyphenated approaches have been reported in 
chemistry, pharmaceutical and food sciences applications44-46. However, the development of 
cryogenic temperature control methods during the sample preparation remains the most 
promising aspect for possible emergence of such technologies in biomedical applications and 
human body fluids analysis47. This present study however investigates the benefits of an 
alternative approach combining centrifugal filtration/fractionation with ATR-IR spectroscopy 
for the analysis of human serum as a proof of principle for monitoring and quantified potential 
low molecular weight biomarkers. Glucose has been used as a model to illustrate the strategy 
to isolate the relevant fraction of the sample to minimize the influence of the HMW proteins 
and improve the precision and accuracy of the quantitative models built using the PLSR 
algorithm. Initially, human serum spiked with systematically varying, physiologically relevant, 
concentrations of glucose will be used to optimise the measurement protocol, including a study 
of how the volume deposited on the ATR crystal influences the relevancy of the data collected. 
PLSR will be employed to build a predictive model over the concentration range to demonstrate 
the principle of the predictive capacity of the technique and the improved precision afforded 
by serum fractionation. In the second part of the study, the technique will be demonstrated in 
patient samples of known varying glucose levels, validating the potential for glucose level 
monitoring. 
  
2.  Experimental  
 
2.1 Materials and Methods 
 
Sterile, filtered human serum from normal mixed pool (off the clot) was purchased from TCS 
Biosciences (UK) for the in vitro model prepared from spiked solutions, while patient serum 
samples were donated by the University Hospital CHU Bretonneau de Tours (France), 
following the institutional ethical procedures. Initially, the samples were collected during 
routine blood check-ups, 1 mL of the vial remains being provided for further spectroscopic 
analysis. Commercially available, centrifugal filtering devices, Amicon Ultra-0.5ml (Millipore 
- Merck, Germany), with cut-off points at 10 kDa, were employed to fractionate the serum 
samples, in both cases. As a result, for each sample, 2 fractions were obtained following 
filtration; the first representing serum constituents with a molecular weight higher than the cut-
off point of the filter used (concentrate); the second corresponding to the fraction passed by the 
membrane and collected in the vial (filtrate). 0.5 mL of the serum was placed in the centrifugal 
filter for spinning. The procedure for washing the centrifugal devices prior to serum processing 
was adapted from48 EDVHG RQ PDQXIDFWXUHU¶V JXLGHOLQHV DQG SHUIRUPHG DV IROORZV 7KH
Amicon Ultra-0.5ml filter was spun thrice with a solution of NaOH (0.1M), followed by 3 
rinses with Milli-Q water (Millipore Elix S). For both washing and rinsing, 0.5 mL of the 
respective liquid was added to the filters and the centrifugation was applied for 10 mins at 14 
000g followed by a spinning with the devices upside down at 1000g for 2 mins in order to 
remove any residual solution contained in the filter. The aim of the study was to illustrate the 
potential of ATR-IR spectroscopy to detect and screen a potential biomarker in the LMWF. 
Therefore, based on previous experience demonstrating that 100% of the LMWF is recovered 
with the 10 kDa, only this cut-off has been included in the present work24. 
Additionally, D-Glucose (Fisher scientific, UK) was analysed as reference chemical compound 
for the quantitative analysis on whole and filtered human serum. Notably, glucose has been 
selected because it is routinely screened in clinics allowing determination of exact blood levels 
for each patient sample tested. 
 
2.2 Glucose Spiked Human Serum model 
 
The commercial whole human serum was supplemented with known concentrations of glucose; 
0.0 mg.dL-1 (control), 20 mg.dL-1, 60 mg.dL-1, 100 mg.dL-1, 140 mg.dL-1, 180 mg.dL-1, 220 
mg.dL-1, in order to explore the dynamic range and sensitivities of the ATR-IR measurement 
of unprocessed and filtered samples. The concentrations have been selected to cover a wide 
range of physiological relevance to simulate hypoglycaemia (<60 mg.dL-1), normal level (70-
110 mg.dL-1) and hyperglycaemia (>120 mg.dL-1), in order to optimise the protocols for 
clinically relevant human serum monitoring using ATR-IR. The serum stock solution has been 
used as a reference to build the regression models and evaluate the sensitivity of the techniques.  
 
 
2.3 Patient samples blood glucose levels 
 
A total of 15 patient samples have been included in the present study. Glucose levels have been 
measured at the CHU de Tours using a Cobas analyser following the in house guidelines for 
routine biochemical analysis. The principle of the test is based on the enzymatic reference 
method with hexokinase, which catalyses the phosphorylation of glucose to glucose-6-
phosphate by ATP49, 50. Subsequently glucose-6-phosphate is oxidized by glucose-6-phosphate 
dehydrogenase, in the presence of NADP, to gluconate-6-phosphate. This reaction is specific, 
with no other carbohydrate being oxidized. The rate of NADPH formation during the reaction 
is directly proportional to the glucose concentration and is measured photometrically in the 
UV. 
Glucose level is one of the most common tests performed during blood check-ups and is 
therefore a perfect model to develop a proof of principle for quantification of low molecular 
weight biomarkers in human serum using ATR-IR spectroscopy. The instrumentation available 
at CHU de Tours has a standard deviation of 0.04 mmol.L-1 (0.721 mg.dL-1), and can therefore 
be considered as the gold standard. Measured glucose concentrations were provided with the 
patient samples and have been used as target values for the PLSR models. A summary of 
information extracted from patient histories is given in Table 1 (see below).  
All patient samples have been processed with the 10 kDa centrifugal devices in order to carry 
out HMWF proteins depletion prior to IR analysis. The reproducibility being a critical point to 
ensure reliability of the results, a set of 10 independent samples (5 unprocessed and 5 filtered 
mixed pool human serum samples) has been tested on the Cobas analyser before and after 
ultrafiltration. Ultimately, it has been demonstrated that the concentration of glucose was 4.0 
+/- 0.1 mmol.L-1 in both unprocessed and filtered samples, demonstrating that glucose can 
freely pass through the membrane of the filters and be quantified in the filtrates recovered. This 
observation correlates with previous testing of reproducibility highlighting the repeatability of 





Glucose blood levels 




1 3.4 61.25 F 33 
2 3.5 63.05 F 36 
3 3.6 64.86 F 64 
4 3.7 66.66 M 31 
5 3.7 66.66 F 30 
6 3.7 66.66 F 87 
7 3.8 68.46 F 26 
8 6.4 115.3 M 73 
9 6.5 117.10 M 65 
10 6.7 120.70 F 58 
11 7.0 126.11 M 75 
12 7.3 131.51 M 53 
13 9.5 171.15 M 79 
14 10.0 180.16 F 63 
15 11.6 208.98 M 63 
 
 
2.4 Data collection using the ATR-IR  
 
ATR-IR spectra were recorded using a Bruker vector 22 equipped with a single reflection 
golden gate ATR accessory (Specac, UK). A diamond top plate with a 45°C incident angle was 
preferred for this study. Penetration depth of the evanescent wave into the sample is both 
wavenumber and sample dependent, but is typically on the order of 1µm. Spectral data were 
the result of 32 scans, with a spectral resolution of 4 cm-1 covering the spectral window 4000 
± 600 cm-1. A background spectrum was also recorded in air (32 scans) and automatically 
ratioed with the sample spectrum by the software. A built-in quality control is automatically 
performed by the operating system (OPUS software) every day upon system start up, ensuring 
the ATR accessory is delivering adequate data and no malfunction of the instrument is detected. 
Liquid human serum solutions: The spectroscopic analysis of samples was performed directly 
after deposition of a drop on the crystal (0.1 µl, 0.2 µl, 0.5 µL, 1 µL and/or 2 µl), following air 
drying. The drying time necessary is directly related to the volume deposited and can be 
affected by external parameters such as room temperature and humidity, but it generally 
comprised between 3-5 mins. Moreover, the effectiveness of the air drying has been confirmed 
in real time following the evolution of the main water band in the range 4000-2500 cm-1 directly 
on screen. The broad water band, with a maximum absorbance between 3270 - 3340 cm-1, is a 
reliable indicator of the dehydration of the sample deposited. The intensity of the band 
gradually decreases as the sample dries, until an equilibrium is reached, at which point no 
further spectral evolution is observed. When the signal has been found to be stable for at least 
60 seconds, the drop is considered dry and the spectra were collected. Although not yet 
automated and requiring the constant presence of the operator to monitor the screen, this 
approach has been found particularly efficient and the complete drying can be unambiguously 
confirmed in the data collected, as illustrated with the raw spectrum in figure 1B. 
At least 5 drops have been measured per sample and sets of 5 spectra have been collected for 
each drop in order to take into account both instrumental and inter-drop variability In order to 
reduce the inter-drop size and shape variability, the deposition has been made on clean and dry 
crystal. It has been observed that the top diamond plate is quite hydrophobic, preventing the 
drop from spreading out after deposition and maintaining the round shape of the liquid sample. 
All drops have been administered with micropipettes, perpendicular to the surface, which 
ultimately results in reproducible circular shaped samples centred on the crystal after air drying. 
Finally, only 20 spectra (4 drops) have be used for each sample, selecting the data sets with 
similar raw maximum absorbance indicating the solutions have been deposited similarly on the 
crystal. Ultimately, a total of 140 spectra were included in the model study with spiked human 
serum, while 300 spectra were analysed for the 15 patient samples. 2 µL has been found to be 
the maximum realistically usable volume, considering the drying time and the large number of 
samples tested.    
 
2.5 Data pre-processing and analysis 
 
The different pre-processing and data analysis steps were performed using Matlab (Mathworks, 
USA). Partial Least Squares Regression (PLSR) analysis was exploited as an approach to 
quantify the spectral variability generated by either the addition of known concentrations of 
glucose to the human serum or estimate blood glucose levels in patient samples. 
The analysis of the spectra collected has been restricted to the finger print region, in which the 
sugar contribution occurs in IR spectra. The spectra collected from spiked human serum have 
been either min-max normalized (MMN) at the 1637 cm-1 peak corresponding to the amide I 
band or processed using baseline correction (rubber-band) followed by vector normalization 
(VN). The IR data collected being highly reproducible with no sign of strong distortion linked 
to physical effects such as Mie scattering, the baseline correction has been mainly employed to 
correct the slight offset observed in the spectra between drops. For instance, the rubber-band 
algorithm employed has been adapted for use on spectral data51. In the present case, only 2 
nodes have been defined at 1800 cm-1 and 900 cm-1 for the baseline correction and this 
consistently for all spectra. To better appreciate the minimal correction applied to the data sets, 
the process is illustrated in Figure S.1. It should be noted that, following filtration, the spectral 
signature is quite different, due to the depletion of the abundant proteins. Consequently, the 
typical Amide I and II bands are not observed in the filtered serum, but are replaced by a strong 
peak at 1591 cm-1 most likely assigned to conjugated C=C. For consistency, this band, which 
is the most intense observed in the spectra of the filtered samples, and is also remote from the 
glucose bands, has been selected for the min-max normalisation.  
In an attempt to preserve the information related to raw absorbance intensity, a different method 
has been employed for the data collected from patient samples. Due to the fact that none of the 
spectral features can be assumed to be consistent between patients, and thus cannot be used as 
internal standard, the min-max normalisation on the amide I band was found to be insufficient 
(data not shown). However, in order to minimise the slight drifts observed the spectral 
background, it has been preferred to normalised the data at 1780 cm-1, located in a region away 
from any IR bands of the serum. This approach was evaluated in this study to compensate from 
the offsets observed in the raw data, restoring a common baseline for the spectra without losing 
the relation between absorbance and the concentrations of different molecular species. The 
PLSR model has been built from the pre-processed data sets. The algorithm works in a 
supervised fashion, whereby all different concentrations are known before running the analysis. 
Ultimately, the output gives an estimation of the model precision (Root Mean Square Error ± 
RMSE) and linearity between the experimental and predicted concentrations (R2). In order to 
validate the robustness of the models, a 20 fold - cross validation loop has been included in the 
routine. For each iteration, 50% of the data is randomly selected to constitute the calibration 
set, while the remaining 50% are used as a validation set for the quantitative predictions. In the 
present study, particular attention has been accorded to exploit the entire outcome of the PLSR 
models. For this, for each iteration of the cross validation the RMSE, R2 and predicted 
concentrations have been extracted and compiled to calculate mean and standard deviations 
values. It is also important to note that, PLSR being a supervised algorithm, spectral variations 
not directly related to the target variable of glucose concentration should have little to no impact 
on the precision estimated. Also the air drying has been carefully monitored for each sample, 
and any residual water variations in the data would not be expressed in the dimensions selected 
for the construction of the quantitative model.         
Finally, the 2 main notions developed throughout the study are the precision, which is the 
variability in the measurements realised, and the accuracy corresponding to the how closely 
WKHUHVXOWRIDQH[SHULPHQWDJUHHVZLWKWKH³WUXH´RUH[SHFWHGUHVXOW:KLOHWKHILUVWFDQEH
given by mean of the RMSEV from the PLSR models and different calculation of standard 
deviation, the latest has been especially used for the patient samples by comparing the relative 
error (%) between the reference concentrations results provided by the clinicians (gold 
standard) and the predicted concentrations estimated by PLSR.       
3.  Results and discussion 
 
3.1 Quantification of Glucose levels in spiked human serum   
3.1.a Selecting volumes deposited 
 
ATR-FTIR appears to be a convenient, rapid and reliable approach to collecting high quality 
spectra from highly concentrated liquid samples such as human body fluids and for instance 
serum52. A drop directly deposited onto the crystal can be analysed without prior dilution to 
avoid saturation effects generally encountered with transmission mode measurements53. 
Despite the rich composition of the human serum, the water contribution remains quite intense 
in the data gleaned from liquid form samples and air drying remains preferable to visualise all 
the spectral features54. Figure 1 presents ATR-IR spectra collected from an air dried aqueous 
solution of glucose (10 gdL-1) (Figure 1A) and human serum (Figure 1B). Following air drying, 
the human serum spectrum displays numerous well defined peaks within the 4000-650 cm-1 
spectral widow, allowing clear identification of specific features of the human serum, for 
example those highlighted in grey at 3280 cm-1 (H±O±H stretching), 2957 cm-1 (Asymmetric 
CH3 stretching), 2920 cm
-1 (Asymmetric CH2 stretching), 2872 cm
-1  (Symmetric CH3 
stretching), 1536 cm-1 (Amide II of proteins), 1453 cm-1 (CH2 scissoring), 1394 cm
-1 (C=O 
stretch of COO±), 1242 cm-1 (Asymmetric PO2 stretch), 1171 cm-1 (Ester C±O asymmetric 
stretch) and 1080 cm-1 (C±O stretch)54-56. The spectrum from whole human serum is clearly 
dominated by the abundant proteins contribution such as albumin and globulins24 which swamp 
the contribution of less represented biomolecules. In comparison, the glucose signature exhibits 
fewer features, the main peaks being located in the spectral range 1280 ± 800 cm-1, resulting 
IURPERWKWKHȞ&²2DQGȞ&²O²C) vibrational modes57, as identified in Figure 1A.  In 
the present work, the limited spectral window of 1800 ± 900 cm-1 was chosen to avoid the 
regions of strong water absorption. Although the spectral response has stabilised, contributions 
of water are still visible as a broad background in the region of ~3300cm-1.   
 
The volume deposited can have an influence on the data collected, depending on the 
concentration of the solutions analysed and the coverage of the crystal achieved. The so-called 
³coffee ring effect´ has been documented extensively in literature54, 58 and describes the uneven 
distribution of the constituents following air drying. Commonly, a higher concentration is 
obtained on the edge of the deposited material which can result in some spectral variability. In 
complex mixtures such as human serum, different chemical constituents are deposited at 
different rates, as described by Vroman59, resulting in spatially inhomogeneous chemical 
composition in the dried deposit. Figure 2 presents the dependence of the area under the curve 
observed in raw data (AUC ± between baseline and peak maximum), calculated for the band 
1180-955 cm-1, depending on deposited volume, for two different concentrations of glucose 
solution. The 10 g.dL-1 solution does not exhibit any noticeable decrease in the AUC between 
0.5 µL and 2µL, explained by a full coverage of the crystal coupled to a saturation of the 
signal24. The notion of saturation is defined by the loss of linearity between the absorbance and 
the concentrations measured. In contrast to transmission IR spectroscopy, which can deliver 
absorbance up to 3 with a saturation manifesting itself as highly noisy spectra coupled to 
plateau effects, ATR-IR spectra intensities are limited by the depth of penetration of the 
evanescent wave. In the present study and considering the instrumentation used, it has been 
observed that the maximum absorbance that can possibly be recorded from protein rich samples 
such as human serum would never exceed 0.45. Following air drying, the Beer-Lambert type 
dependence of the absorbance on initial sample concentration and length of the optical path 
can both be partially lost and the critical parameter is the amount of matter deposited. In other 
words, the deposited sample thickness, and therefore absorbance, depends on the concentration 
of the droplet applied, but if the sample thickness exceeds the evanescent wave penetration 
depth, no further increase in the absorbance can be observed. However, when reducing the 
volume below 0.5 µL, the deposit thickness becomes less than the sampling depth, and the 
AUC consequently decreases. The AUC pattern for the 0.1 g.dL-1 is rather different, a 
maximum intensity being found with 0.2 µL. This is a result of the coffee ring effect, as the 
glucose is accumulated in the edges of the drop, outside the field of data collection for larger 
volumes (Figure 2, 0.5 µL ± 1 µL ± 2 µL ), thus delivering poor signals, while the 0.2 µL 
deposit is completely contained on the crystal and entirely recorded. The decrease observed for 
the 0.1 µL sample confirms that the drops are smaller than the ATR crystal area. These 
observations clearly demonstrate the difficulty to accurately estimate the maximum and 
minimum glucose concentrations that can be measured with IR, due to the different behaviours 
at low and high concentrations. However, as demonstrated in the supplementary material 
(Figure S.2), based on the amount of glucose deposited, such limits can be estimated. Also, as 
the highest concentrations measurable are much greater than any relevant range for clinical 
applications, with values between 1210 mg.dL-1 and 24205 mg.dL-1 for respectively 2 µL and 
0.1 µL drops, the minimum concentrations are indeed of far more importance. While a 0.1 µL 
drop would be associated with a limit of detection around 15 mg.dL-1, increasing the volume 
deposited would gradually decrease the minimum concentrations measurable to 7.5 mg.dL-1, 3 
mg.dL-1, 1.5 mg.dL-1and 0.75 mg.dL-1for respectively 0.2 µL, 0.5 µL, 1 µL and 2 µL. Such 
observation implies that larger volumes should deliver more accurate outcomes from the 
analysis, however further investigations of human serum have been performed with both 2 µL 
and 0.2 µL. Although 0.1 µL would have been optimum to ensure the volume deposited is 
smaller than the crystal size, due to the viscosity of the serum, the smallest volume that could 
be deposited as drops was 0.2 µL.  
 
 
3.1.b Construction of the quantitative model: Partial Least Square Regression (PLSR) 
 
Before analysing the patient samples, a quantitative model has been built using the PLSR 
algorithm and applied to the glucose spiked human serum models in order optimise the protocol 
for measurement, including deposit volume, and to evaluate the impact of centrifugal filtration 
on the sensitivity and accuracy of the technique.  
The first step of the study was to build a model accurately mirroring clinically relevant blood 
variations of glucose levels using human serum spiked with D-glucose. For this, different 
amounts of pure glucose have been added to the human serum stock solution in order to achieve 
variable concentrations in the physiologically relevant range of 20 mg.dL-1 ± 220 mg.dL-1. The 
normal glucose concentration being between 70 mg.dL-1 and 110 mg.dL-1, simulation for 
hypoglycaemia and hyperglycaemia have been deliberately included in the set of samples 
prepared and tested. Figure 3A presents mean ATR-IR spectra collected following air drying 
from the different solutions. The (1637cm-1) min-max normalized data exhibit similar profiles, 
only the region attributed to sugar being affected by the increase of glucose concentration. In 
Figure 3B, it can be observed how the 1140 ± 950 cm-1 spectral region evolves from the serum 
stock solution (red) to the highest concentration prepared (cyan), the main features at 1105 cm-




Pre-processed spectra have been analyzed using the PLSR algorithm to determine the 
relationship between spectral variations and glucose concentrations. The method being 
supervised, the different concentrations are taken into account during the calculations. The first 
step generates a scatter plot, (not shown). Figure 4 presents the first two weighting vectors A 
and B, confirming the discrimination of the data is based on glucose features, which, as 
demonstrated in Figure 2 and 3, mainly occur in the 1190-950 cm-1 window. The similarities 
between the 2 weighting vectors support the fact that more than 1 dimension is required to fully 
describe the spectral variability due to glucose concentrations. Plotting the Root Mean Square 
Error from the validation set (RMSEV) as displayed in Figure 5 is commonly used to guide the 
operator in choosing the optimal number of dimensions necessary to reach the best model. In 
the present case, a 20 fold cross validation has been preferred, leading to the creation of 20 
independent calibration/validation sets and thus 20 predictive models. In order to simplify the 
illustration, the error bars in Figure 5 illustrate the standard deviation calculated between each 
iteration of the cross validation. As expected, a strong decrease in the RMSEV is observed 
within the 3 first dimensions, which is normal behaviour for well discriminated data, followed 
by a stabilisation of the values observed without any further improvement of the model 
precision. Considering the min-max normalised spectra used for illustration in Figure 5, a 
minimum is found at 2.078+/-0.252 mg.dL-1, corresponding to 8 dimensions. For consistency 
between data sets, the minimum found has always been selected to build the predictive models. 
It should be noted that similar plots can be obtained from the RMSE for the Calibration sets 
(not shown).  
 
Ultimately, after selection of the optimal number of dimensions for the data set analysed, a 
predictive model can be built from the PLSR scatter plot (Figure 4), to compare the 
observations corresponding to the known concentrations of glucose in the samples with the 
estimated concentrations from the spectral data sets. In the example presented in Figure 6, a 
really good linearity was reached, with a R2 value of 0.9992. The standard deviation (2.172e-4) 
is indicative of good repeatability between the 20 iterations of the cross validation. However, 
the standard deviation of the RMSEV (0.2526 mg.dL-1) is equal to about 10% of the mean 
value, but remains acceptable considering the precision of the model is below the mg.dL-1 
range. Moreover, the error bars display no overlapping of data, indicating that each 
concentration can be unambiguously identified. This approach has been replicated for all data 
sets collected from the human serum samples spiked with glucose, either unprocessed (whole 
serum) or following centrifugal filtration with a 10 kDa device. The summary of the PLSR 
results is presented in Tables 2 and 3.  
 
 
3.1.c Summary of results from unprocessed whole human serum spiked wih glucose 
 
As detailed in Figure 2, the deposition of 2 µL and 0.2 µL drops has been used to illustrate 2 
distinct experimental conditions corresponding to a coverage exceeding the ATR crystal, after 
air drying of the samples, compared to a coverage less than the recording area. The objective 
is to better understand how the volume of the deposit can influence the relevancy of the data 
collected, notably in relation to the coffee ring effect. It has been documented that such an 
effect can result in variations of the distribution of molecular species.      
A direct comparison of the predictive results obtained from 2 µL and 0.2 µL (Table 2) drops 
of whole human serum unambiguously demonstrates that the precision of the PLSR models is 
strongly affected by the size of the drops. The best RMSEV (2.078+/-0.252 mg.dL-1) was 
achieved with the Min-Max Normalised (MMN) ATR-IR spectra collected from the 2 µL 
drops, while this value is up to 6 times higher for the 0.2 µL deposits (12.347 +/- 1.852 mg.dL-
1). It should be noted that neither reducing the spectral range of the glucose windows (1190-
950 cm-1) (See Table 2 GLU) nor using vector normalisation (VN) improves the precision of 
the predictive models. (See Table 2 VN) This observation is rather encouraging and supports 
the notion that, although the samples exhibit a heterogeneous distribution of the different 
molecular species following air drying, the centre of the drop still delivers quantitative 
information that can be linearly captured by the PLSR models.  
Interestingly, the 0.2 µL does not improve the PLSR quantitative model, which suggests that 
attempting to ensure that the entire sample is deposited on the ATR crystal, with a coverage 
less than the recording area, is not the best strategy when performing ATR analysis. An 
experimental limitation of ATR-IR spectroscopy is the absence of a bright field imaging system 
coupled to the spectrometer, making the visualisation of the drop positions quite difficult, 
especially with volumes less than 1 µL. Therefore, it is simply impossible to ensure the 0.2 µL 




   Table 2: Summary of PLS results for the unprocessed human serum analysis 
Deposit type Drop - 2 µL Drop - 0.2 µL 
 RMSEV STD R2 RMSEV STD R2 
MMN 
FP 2.078 0.252 0.999 12.347 1.852 0.974 
GLU 2.388 0.126 0.999 15.419 0.753 0.96 
VN 
FP 2.137 0.181 0.999 12.512 1.36 0.973 
GLU 2.806 0.362 0.999 15.942 2.058 0.956 
MMN: min-max normalised at 1637 cm-1; VN: baseline and vector normaised, STD: standard deviation, GLU: spectra cut to the range 1190-
950 cm-1  
 
3.1.d Summary of results: 10 kDa filtered human serum spiked with glucose 
 
Centrifugal filtration has been used to fractionate the human serum and isolate chemical 
populations depending on their molecular masses. In the present study, a 10 kDa centrifugal 
device was used in order to specifically deplete the abundant proteins such as globulins and 
albumin24 and retain only the molecular species with low molecular weight in the filtrate, below 
the cut-off point of the membrane, for subsequent spectroscopic analysis. For instance, glucose 
is about 180 Daltons, which means it will freely pass through the membrane during spinning 
of the human serum. Using such an approach, the complex mixture of the human serum can be 
partially simplified, removing some of the most dominant proteins such as albumin and 
globulin, consequently enhancing the contribution of underlying constituents in the IR 
signatures collected as illustrated in Figure 7. For the 10 kDa filtered serum model, the 
measurement of deposits from the 2 µL drops deliver the best predictive model with a RMSEV 
value of 2.199±0.250 mg.dL-1 for the MMN data. As for the unprocessed whole human serum, 
no improvement can be obtained with deposits from smaller volumes (0.2 µL), but rather an 
increased RMSEV of 5.337± 0.551 mg.dL-1 is observed, indicating once more that precision in 
the sample deposition on the ATR crystal is a crucial aspect for this experimental set up. 
However, as witnessed earlier, the centre of the dried samples preserve the linear relation 
between glucose concentrations and spectral variations. This is a significant observation as, 
following the centrifugal filtration, the overall concentration of the serum filtrate is strongly 
diminished due to depletion of the abundant proteins. The thickness of material deposited from 
the same volume is therefore significantly reduced, potentially below the region of saturation 
of the STR sampling (Figure 2). The high degree of variability in the raw spectral intensities is 
compensated by the normalisation of the data prior to PLSR analysis. Ultimately, values of the 
RMSEV of 2.078±0.252 mg.dL-1 and 2.199±0.250 mg.dL-1 for, respectively, the unprocessed 
and filtered serum are not significantly different, within the standard deviation associated with 
them (Table 3).  
This initial step of the study is rather reassuring, indicating that centrifugal filtration does not 
affect the sample integrity, which remains representative of the concentrations of the different 
serum physiological constituents. The main concern was regarding the drying pattern of 
biological samples characterised by low concentrations, as illustrated in Figure 2, which are 
more affected by the coffee ring effect which could result in a drastic decrease in the IR spectral 
intensity due to accumulation of molecules in the edge of the dried drop, with little or no 
contribution at the centre of it. However, despite the considerably reduced concentration in 
filtered serum, this effect remains limited and the recordings performed on the 2 µL drops are 
perfectly relevant, delivering good predictive models by means of PLSR analysis. Following 
those observation, the use of 0.2 µL samples can be disregarded for analysis of patient samples, 
in favour of the 2 µL. A comparison with a PLSR model constructed from aqueous glucose 
solutions indicates that the coffee ring effect is limited in filtered serum. In pure glucose 
solutions, it is observed that the RMSEV tends to be slightly higher than those obtained in 
Table 3. (See Figure S.4). The small drop in the R2 value (0.9987) illustrates the difficulty to 
get a linear correlation between spectral variations and concentrations for pure glucose 
solutions. It also supports the fact that the residual serum constituents present in the 10 kDa 
filtrates play a key role in maintaining a more consistent drying pattern while reducing the 
coffee ring effect. Thus, it is important to deplete the human serum and remove the HMW 
fraction, but preserving the whole LMW fraction seems to be a better approach than trying to 
further separate or extract glucose from the samples as the surrounding matrix clearly impacts 
the precision of the measurements done.  
 
 
Table 3: Summary of PLS results for the 10KDa filtered human serum analysis 
Deposit type Drop - 2 µL Drop - 0.2 µL 
 RMSEV STD R2 RMSEV STD R2 
MMN 
FP 2.199 0.250 0.999 5.337 0.551 0.995 
GLU 3.465 0.317 0.998 5.506 0.417 0.995 
VN 
FP 2.679 0.234 0.998 5.357 0.396 0.995 
GLU 4.001 0.337 0.997 8.746 0.539 0.986 
MMN: min-max normalised at 1591 cm-1; VN: baseline and vector normaised, STD: standard deviation, GLU: spectra cut in range 1190-950 
cm-1  
 
3.2 Glucose level quantification in patient samples 
Although the quantitative capabilities of ATR-IR spectroscopy can be quite easily 
demonstrated with model human serum spiked with glucose, both purchased online, the 
analysis of patient samples can be considered a more delicate matter, the main reason being the 
multi-parametrical variability observed in clinical applications. When spiking human serum 
with glucose, only one physiological constituent is affected, while all others remain at similar 
levels. In that situation, any peak away from the glucose spectral window can be used as an 
internal standard for calibration of the data, explaining the good results obtained with a MMN 
to the amide I band. The overall protein content being the same between spiked samples, the 
multivariate analysis of the spectra ultimately highlights the linear evolution of the band ratio 
between the proteins and glucose. However, samples harvested from patients can display an 
intrinsic variability, directly reflecting their physiological state on the day. In real conditions, 
there is no real control, as each individual has its own metabolism, characterised by different 
ground blood levels for all the serum constituents. Uric Acid, Blood Urea Nitrogen (BUN), 
Creatinine, total proteins (albumin, globulin), Total Bilirubin, Alkaline Phosphatase, GGTP, 
LDH, SGOT (also called AST) are some of the most screened serum constituents, although 
only a few are routinely tested. Glucose is indeed one of them, used for monitoring either 
hypoglycaemia or hyperglycaemia, particularly important for the detection of diabetes. In 
addition to the fact that glucose can freely diffuse through the centrifugal device membranes 
and be fully collected in the filtrate, the choice of the glucose was also motivated because of 
its physiological relevance and normal levels in human serum. With concentrations ranging 
between 70-100 mg.dL-1, it can be detected in whole unprocessed serum, which was the 
condition required to be able to build a comparative model between patients samples before 
and after fractionation. 
A total of 15 patient samples have been analysed using ATR-IR spectroscopy, selected to cover 
a wide range of glucose concentrations mirroring cases of hypoglycaemia and hyperglycaemia 
(Table 1). The initial measurements have been performed from the unprocessed samples, as 
provided from the clinician, from 2 µL air dried drops. Similarly to the spiked samples, the 
spectra, min-max normalised at 1780 cm-1, have been analysed with the PLSR algorithm and 
the results are presented in Figure 9A. With a RMSEV of 11.87 +/- 0.88 mg.dL-1, the precision 
of the predictive model has strongly decreased in comparison to the observation made from 
spiked serum. Furthermore, the R2 reflects the lack of linearity between the spectral variations 
and the glucose levels, thus the poor quality of the analysis performed. As shown in Figure 8B, 
although the first (a) and second (b) PLSR weighting vectors contain contributions which can 
be associated with glucose (Figure 1), there are also significant other contributions associated 
with serum proteins in the region 1650-1350 cm-1. 
Following the first set of measurements, the same patient samples have been processed with a 
10 kDa centrifugal device in order to fractionate the serum by depletion of the abundant 
proteins. From the resulting filtrates, ATR-IR spectra have been recorded, also min-max 
normalised at the 1780 cm-1 and analysed in identical conditions for comparison purposes. The 
PLSR model is presented in Figure 9B, displaying a much better RMSEV value (3.1 ± 0.13 
mg.dL-1). A comparison of both plots unambiguously supports the improvement after 
centrifugal filtration that can be achieved, confirmed by the reduced standard deviation 
associated with each concentration tested. Consequently, the linearity of the predictive model 
is restored to an acceptable value for R2 of 0.9957. The first (a) PLSR weighting vector, shown 
in Figure 8D, still contains significant contributions associated with serum proteins in the 
region 1650-1350cm-1, although the spectrum (b) of the second is now dominated by glucose.  
Table 4 gives an overview of the different predicted concentrations for each patient for both 
unprocessed and fractionised samples. The mean values from the 20 cross validations iterations 
are given in mg/mL with the corresponding standard deviation and finally the relative error 
compared to the real glucose concentration, as given by the clinician, has been expressed in 
percentage. Ranging from 16.39% to 0.25%, the relative error for the unprocessed serum 
clearly highlights the difficulties to estimate the glucose levels in whole serum. Indeed some 
of the samples display acceptable mean predictive values because of the supervised fashion of 
the PLSR algorithm. As for any calibration curve, the trend line illustrates the best fit between 
data point, meaning few samples are located close to it. In comparison, the filtered serum 
delivers higher accuracy, ranging from 2.51% to 0% mean relative error. Looking at the 
samples independently, it can be seen that the majority of them are below 1% relative error, 
clearly supporting the increased accuracy of the model with fractionated samples. 
Considering the complexity of human serum, concerns can be raised towards the monitoring 
of low molecular weight physiological constituents potentially relevant for diagnosis. The 
proof of principle presented throughout this study demonstrates that glucose levels, a well-
known biomarker for diabetes, can be monitored by means of infrared spectroscopy. As 
highlighted in Figure 1, specific spectral features can be identified for the detection of glucose 
in complex biological mixtures. Moreover, using multivariate analysis tools such as PLSR, a 
linear relation between glucose levels and the intensity of glucose spectral features can be 
obtained. The interferences presented by the HMWF of the human serum is illustrated in the 
case of patient samples (Figure 9), indicating that the presence of the abundant proteins can be 
identified as a limiting factor when focusing the spectral analysis of potential low molecular 
weight biomarkers. Similarly to glucose, the constituents of the LMWF of the serum can 
exhibit weak contributions in the IR data collected directly impacting on the precision and 
accuracy of the quantitative models developed. The concept of human serum fractionation 
proposed in the present work, implies that separating the fractions of interest to perform 
spectral characterisation independently would ultimately lead to better accuracy. This 
statement can be further supported by the presence of 3 different patients with similar glucose 
concentrations as given by the clinicians. Although patients 4, 5 and 6 all have glucose levels 
found at 66.6 mg.dL-1, all individuals tested would logically present different overall serum 
composition, notably with consequent variations in the protein contents. While the predictive 
model built from the whole serum delivers glucose concentrations of respectively 73.44 mg.dL-
1, 66.94 mg.dL-1and 67.04 mg.dL-1, after depletion of the abundant proteins, those values are 
found to be 65.66 mg.dL-1, 67.16 mg.dL-1and 67.02 mg.dL-1. Although the analysis is not able 
to generate exact glucose concentrations for those 3 patients due to the precision of the model, 
it is noticeable that the inter-individual variability is considerably reduced, leading to improved 
accuracy. Instrumentation available in clinics present high performance towards glucose level 
monitoring, and with a standard deviation of 0.72 mg.dL-1 (0.04 mmol.L-1), it is hardly 
conceivable that IR can deliver better results. Although with a RMSEV of 3.1 +/- 0.13 mg.dL-
1, fractionating the human serum before analysis places the ATR-IR approach in a clinically 
relevant range of concentrations allowing the identification of patients with abnormal glucose 
levels (either hypo- or hyper-glycaemia), the aim of the work proposed was to further 
demonstrate the potential for body fluids screening towards disease diagnosis, in general. 
However, the precision of the model expressed by the RMSEV indicates the lowest variations 
in glucose concentration that can be considered statistically relevant for the discrimination of 
2 patients with close results. More importantly, the precision and accuracy play key roles in 
identifying patients at risk, according to blood glucose (BG) falling in the range corresponding 
to hypoglycaemia or hyperglycaemia. For this reason, the detection and monitoring of 
biomarkers are subject to requirements specifically defined by the clinical context. For 
instance, when considering blood glucose monitoring, the concept of the Parkes error grid has 
been implemented in 1994 59. This model defines performance zones for the results collected, 
aiming to assess the clinical accuracy of BG monitoring devices. Notably, the Parkes error grid 
has been introduced as an accepted evaluation tool according to the ISO15197:2013 guideline 
³In vitro diagnostic test systems -- Requirements for blood-glucose monitoring systems for self-
testing in managing diabetes mellitus´([DPSOHRI3DUNHVHUURr grids constructed from the 
PLSR analysis performed from whole and filtered patient serum are given in Figure 10. Each 
estimated value from both PLSR models (3000 predicted concentrations) has been plotted in 
order to better visualize their distribution across the risk zones (it should be noted that the 
model is based on Diabetes type I). While for the whole serum, a majority of the values are 
IRXQG LQ]RQH$GHILQHGDV WKH]RQHRI³FOLQLFDODFFXUDWHPHDVXUHPHQWVZLWKQRHIIHFWRQ
FOLQLFDODFWLRQ´LWFDQ also be observed that, for the lowest concentrations, many are located in 
zone B. A general consensus would support that, based on the definition of the risk boundaries, 
a clinically accurate BG meter should show at least 95% of its data points in zone A of the 
Parkes error grid. Although the number of patients in the present study remains limited, it is 
nevertheless interesting to observe the significant improvement obtained after depletion of the 
abundant proteins by ultrafiltration and how all the predicted concentrations from the PLSR 
model are now gathered in zone A, unambiguously removing any doubts about the data 
interpretation (Figure 10B). This further supports the increased clinical relevancy of the 
quantitative measurement performed after isolation of the LMW fraction. Recently, an 
increasing numbers of publications promote the capabilities of IR and Raman spectroscopy for 
serum analysis in both animal and human models from cardiovascular disease to cancers 
diagnosis61-63. However even facing the difficulties to accurately perform specific 
discrimination or diagnosis2, 53, resorting to pre-analytical sample preparation procedures is 
rarely or never considered. Ultimately, the benefits of serum fractionation using centrifugal 
filtration demonstrated in the case of glucose levels can be easily transferable to any other low 
molecular weight biomarkers with swapped contribution in the IR data by the HMWF. Indeed, 
the transferability into clinics remains an open discussion and further in depth investigation is 
needed to better evaluate the place of centrifugal filtration in medical routines. However, 
separation techniques such as those based on chromatography hold a pivotal position in 
diagnosis based on proteomics, peptidomics or metabolomics. Considering the cost to equip a 
service with an operational LC/MS systems, the labour intensive procedure for sample 
preparation and analysis and the running costs attached to maintenance of the instrumentation, 
the IR approach coupled to centrifugal filtration remains a competitive and cost effective 
alternative, especially in cancer detection. The centrifugal filters can generate enough sample 
for analysis in less than a minute and, although they can represent an additional cost to patient 
testing, compared to protocols involving electrophoresis and/or immunoassays, the 3 euros per 
device (around 3 dollars) could appear to be insignificant. However, this study remains a proof 
of concept and the emergence of new technologies for automated sample fractionation and 
protein depletion based on similar membrane based principle may be necessary (e.g. 
microfluidic based) for translation of such an approach to the clinical environment. Therefore 
such optimisations would contribute to further broaden the range of applications of vibrational 
spectroscopic techniques.  
 
 Table 4: Summary of PLS results for the unprocessed and 10 kDa filtered human serum patient 
samples. 
 
Unprocessed serum 10 kDa Filtered serum 




Mean STD % Mean STD % 
1 61.25 65.39 9.84 6.75 61.68 2.45 0.71 
2 63.05 52.71 11.46 16.39 63.05 3.74 0.00 
3 64.86 70.34 7.59 8.45 65.37 2.73 0.78 
4 66.66 73.44 10.69 10.17 65.66 3.04 1.51 
5 66.66 66.94 10.98 0.42 67.16 2.68 0.76 
6 66.66 67.04 9.90 0.58 67.02 3.66 0.55 
7 68.46 73.71 7.62 7.67 70.18 3.33 2.51 
8 115.3 116.54 8.49 1.08 112.92 2.65 2.06 
9 117.1 112.04 10.04 4.32 116.30 2.42 0.69 
10 120.7 115.32 8.68 4.46 122.65 1.90 1.61 
11 126.11 127.20 7.44 0.86 126.64 2.89 0.42 
12 131.51 126.72 8.91 3.64 131.43 3.39 0.06 
13 171.15 175.12 9.48 2.32 171.44 2.50 0.17 
14 180.16 180.61 7.16 0.25 179.03 2.77 0.63 
15 208.98 202.37 9.66 3.16 209.01 3.00 0.01 
   Mean % = 4.7  Mean % = 0.84     
STD: standard deviation; %: relative error between referecence and mean predicted value expressed in percent  
 
   
4.  Conclusion 
Screening of human serum, and by extension all body fluids, is still an emerging field of 
application and in order to strengthen the position of Infrared spectroscopy as a potential 
clinical tool, numerous questions need to be considered and addressed by the community. 
Firstly, the technique should be competitive with other approaches currently used, such as Mass 
spectroscopy, in terms of sensitivity and specificity, and, secondly, it should be able to deliver 
information relevant for clinical diagnosis. Infrared spectroscopy holds immense promise for 
the implementation of new quantitative analytical techniques in clinical routines. The label 
free/reagent free argument is often used to further support the relevancy to develop such 
techniques. However, in order to comply with the high requirements associated with body 
fluids based diagnostics, a number of improvements of the experimental protocol can be 
proposed. Notably, delivering quantitative information of the different serum constituents is 
crucial to validate the approach as a potential clinical tool. Centrifugal filtration of human 
serum has been proposed to specifically isolate relevant fractions of the samples for more 
accurate spectroscopic analysis. Using glucose as an example, it has been clearly illustrated 
that the depletion of the abundant proteins has greatly reduced the spectral variability and 
consequently significantly improved the precision and accuracy of the quantitative models for 
potential low molecular weight biomarkers built from the PLSR analysis. In the present study, 
it has been highlighted that the patients samples are characterised by a normal variability, 
reflecting the physiological state of the individuals tested, but also that such effects can be 
considerably reduced by means of easy and rapid pre-analytical samples preparation steps. 
Furthermore, as the sample processing is also applicable to a wider range of body fluids, the 
methodology presented in the present work will certainly be beneficial for the field and lead to 
drastic improvements in the strategies oriented toward their implementation as the next 
generation of diagnostics techniques clinical tools.     
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Figure 1: Typical ATR IR spectra collected from a 2 µL drop of 10 g.dL-1 pure glucose solution deposited on the ATR crystal 
(A) and human serum (B). Both spectra have been recorded after air drying. No pre-processing has been applied. The spectra 
have been offset for clarity and the main features of interest in the serum spectrum are highlighted.      
 
Figure 2: Evolution of Area Under the Curve (AUC) of the band at 1180-955 cm-1 as a function of volume of glucose solution 
deposited. Red: 10 g.dL-1 glucose solution; Blue: 0.1 g.dL-1 glucose solution. Intensity of the blues bars have been multiplied 
by 5 for better visualization on the graph. Error bars are the results of 5 independent measurements. 
 
Figure 3: Mean ATR-IR spectra collected from unprocessed whole human serum (red) and supplemented with 20 mg.dL-1 
(blue), 60 mg.dL-1 (green), 100 mg.dL-1 (yellow), 140 mg.dL-1 (black), 180 mg.dL-1 (magenta) and 220 mg.dL-1 (cyan) of 
glucose respectively. A: Finger print region 1800-900 cm-1; B: Glucose region 1190 ± 900 cm-1. Min-Max normalized spectra 
on the amide I band (1637 cm-1) used for illustration. 
 
Figure 4: First (A) and second (B) PLS weighting vector corresponding respectively to dimension 1 and 2 of the scatter plot. 
Min-Max normalized spectra on the amide I band (1637 cm-1) used for illustration. 
 
Figure 5: Evolution of the root mean square error on the validation set (RMSEV) according to the number of dimensions 
selected in the PLS model. Value are average calculated from the 20 iteration of the cross validation associated to 
corresponding error bar illustrating the standard deviation. Min-Max normalized spectra on the amide I band (1637 cm-1) 
used for illustration. 
 
Figure 6: Predictive model build from the PLS analysis. For each concentrations the value displayed is an average of the 
concentration predicted with the corresponding standard deviation calculated from the 20 iterations of the cross validation. 
Mean RMSEV and R2 values are given on the plot both also with their respective standard deviation. Min-Max normalized 
spectra on the amide I band (1637 cm-1) used for illustration. 
 
Figure 7: Mean ATR-IR spectra collected from human serum stock solution unprocessed whole (A) and 10 kDa (B) in the 
finger print region 1800-900 cm-1. Spectra offset for clarity 
 
Figure 8: Evolution of the root mean square error on the validation set (RMSEV) according to the number of dimensions 
selected in the PLS model with corresponding first (a) and second (b) PLS weighting vector corresponding respectively to 
dimension 1 and 2 of PLSR model. A: unprocessed serum; B: 10 kDa filtered serum. 
 
Figure 9: A: Predictive model built from the PLS analysis of patient unprocessed samples; B: Predictive model built from the 
PLS analysis of patient 10kda filtered samples. For each concentrations the value displayed is an average of the concentration 
predicted with the corresponding standard deviation calculated from the 20 iterations of the cross validation.  Mean RMSEV 
and R2 values are given on the plot both also with their respective standard deviation. Min-Max normalized at 1780 cm-1. 
Figure 10: Parkes error grid for patient serum samples. A: Predicted values obtained from the PLSR analysis performed on 
the whole human serum from patients. B: Predicted values obtained from filtered human serum. Labels A-E define the risks 
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Figure 1: Typical ATR IR spectra collected from a 2 ʅ> drop of 10 g.dL-1 pure glucose solution 
deposited on the ATR crystal (A) and human serum (B). Both spectra have been recorded after air 
drying. No pre-processing has been applied. The spectra have been offset for clarity and the main 
features of interest in the serum spectrum are highlighted. 
Figure 2: Evolution of Area Under the Curve (AUC) of the band at 1180-955 cm-1 as a function of 
volume of glucose solution deposited. Red: 10 g.dL-1 glucose solution; Blue: 0.1 g.dL-1 glucose 
solution. Intensity of the blues bars have been multiplied by 5 for better visualization on the 
graph. Error bars are the results of 5 independent measurements. 
Figure 3: Mean ATR-IR spectra collected from unprocessed whole human serum (red) 
and supplemented with 20 mg.dL-1 (blue), 60 mg.dL-1 (green), 100 mg.dL-1 (yellow), 
140 mg.dL-1 (black), 180 mg.dL-1 (magenta) and 220 mg.dL-1 (cyan) of glucose 
respectively. A: Finger print region 1800-900 cm-1; B: Glucose region 1190 ʹ 900 cm-1. 
Min-Max normalized spectra on the amide I band (1637 cm-1) used for illustration. 
Figure 4: First (A) and second (B) PLS weighting vector corresponding respectively to dimension 1 
and 2 of the scatter plot. Min-Max normalized spectra on the amide I band (1637 cm-1) used for 
illustration. 
Figure 5: Evolution of the root mean square error on the validation set (RMSEV) according to the 
number of dimensions selected in the PLS model. Value are average calculated from the 20 
iteration of the cross validation associated to corresponding error bar illustrating the standard 
deviation. Min-Max normalized spectra on the amide I band (1637 cm-1) used for illustration. 
Figure 6: Predictive model build from the PLS analysis. For each concentrations the value 
displayed is an average of the concentration predicted with the corresponding standard deviation 
calculated from the 20 iterations of the cross validation. Mean RMSEV and R2 values are given on 
the plot both also with their respective standard deviation. Min-Max normalized spectra on the 
amide I band (1637 cm-1) used for illustration. 
Figure 7: Mean ATR-IR spectra collected from human serum stock solution unprocessed whole (A) 
and 10 kDa (B) in the finger print region 1800-900 cm-1. Spectra offset for clarity 
Figure 8: Evolution of the root mean square error on the validation set (RMSEV) according to the 
number of dimensions selected in the PLS model with corresponding first (a) and second (b) PLS 
weighting vector corresponding respectively to dimension 1 and 2 of PLSR model. A: unprocessed 
serum; B: 10 kDa filtered serum. 
Figure 9: A: Predictive model built from the PLS analysis of patient unprocessed 
samples; B: Predictive model built from the PLS analysis of patient 10kda filtered 
samples. For each concentrations the value displayed is an average of the 
concentration predicted with the corresponding standard deviation calculated from 
the 20 iterations of the cross validation. Mean RMSEV and R2 values are given on the 
plot both also with their respective standard deviation. Min-Max normalized at 1780 
cm-1. 
Figure 10: Parkes error grid for patient serum samples. A: Predicted values obtained 
from the PLSR analysis performed on the whole human serum from patients. B: 
Predicted values obtained from filtered human serum. Labels A-E define the risks zone 
restricted to the range 0-250 mg/dL
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S.1 Data pre-processing: Baseline correction and vector normalisation 
 
 
Figure S.1 illustrates examples of ATR-IR spectra baseline correction and vector normalisation. 
The data collected from mixed pool human serum spiked with increasing concentrations of 
glucose exhibit similar backgrounds. The ATR minimises strong baseline distortion related to 
Mie scattering which leads to simplified data pre-processing requirements (Figure S.1 A). For 
instance, although the baseline correction is based on a rubber band algorithm, only 2 nodes at 
1800 and 900 cm-1 are required in order to compensate for a slight offset that can be observed 
in the data ( Figure S.1 B). Finally, a standard vector normalisation is applied to scale up of the 
spectra for direct comparison and analysis by means of PLSR.   
 
 
Figure S.1: Example of data processing. A: Raw infrared spectra collected from human serum 
spiked with different glucose concentrations. B: Same data set after baseline correction using 
the rubber band algorithm. C: Same data after vector normalisation. Spectra are colour coded 
as follows; Red: Human serum stock solution, Green: serum spiked with 20 mg.dL-1, Blue: 
serum spiked with 60 mg.dL-1, Yellow: serum spiked with 100 mg.dL-1, Black: serum spiked 
with 140 mg.dL-1, Magenta: serum spiked with 180 mg.dL-1 and Cyan: serum spiked with 220 













 S.2 Pure Glucose 
 
S.2.1. Minimum and maximum concentrations   
 
 
In such studies, it is also interesting to address the question of the limit of detection for a given 
molecule, for instance glucose. While the PLSR model delivers information related to 
quantitative precision, working with air dried samples can lead to questions of the maximum 
and minimum of glucose concentrations which can be analysed. As documented previously, the 
behaviour of the spectral changes is not similar for low and high concentrations and thus the 
limitations need to be considered separately24. Figures S.2 A and B display correlations of the 
amount of glucose deposited on the crystal and the measured absorbance in the Area Under the 
Curve (AUC) for the glucose bands in the region 1180-955 cm-1. The Table in Figure S.3 gives 
an overview of the maximum and minimum concentrations of glucose measurable with ATR-
IR, depending on the drop size use for the recording. It is notable that, with a limit of detection 




Figure S.2: Estimation of the limit of detection for ATR-IR analysis of glucose solutions. A: 
linear fitting for amount of glucose below 0.2 µg. B: Polynomial fitting for amount of glucose 







Figure S.3: Summary minimum and maximum concentrations hat can be analysed depending 
on the drop size deposited on the ATR crystal. Concentrations expressed in mg/dL for 
comparison with clinical results.  
 
 





Figure S.4: PLSR model constructed from IR spectra collected from aqueous glucose solutions. 
Similar to patient samples, 2 µL drops air dried before recording have been analysed. A: 
Evolution of the root mean square error on the validation set (RMSEV) according to the number 
of dimensions selected in the PLSR model. Values are averages calculated from the 20 
iterations of the cross validation associated with the corresponding error bar illustrating the 
standard deviation. B: Predictive model built from the PLSR analysis. For each concentration, 
the value displayed is an average of the concentration predicted with the corresponding standard 
deviation calculated from the 20 iterations of the cross validation. Mean RMSEV and R2 values 
are given on the plot both also with their respective standard deviation.  
 
